The Full Wiki

More info on UR-AK49

UR-AK49: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

UR-AK49
Systematic (IUPAC) name
3-cyclohexyl-N-[(3-1H-imidazol-4-ylpropylamino)(imino)methyl]propanamide
Identifiers
CAS number  ?
ATC code  ?
PubChem  ?
Chemical data
Formula C 16H27N5O 
Mol. mass 305.417 g/mol
SMILES eMolecules & PubChem
Synonyms UR-AK49
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

UR-AK49 is a drug used in scientific research which acts as a potent antagonist for the Neuropeptide Y / Pancreatic polypeptide receptor Y4, and also as a partial agonist at the histamine receptors H1 and H2.[1] UR-AK49 is a pure antagonist at Y4 with no partial agonist effects, and although it is only slightly selective for Y4 over the related Y1 and Y5 receptors, as the first non-peptide Y4 antagonist developed UR-AK49 is expected to be useful in the study of this receptor and its role in the body.[2]

References

  1. ^ Xie SX, Kraus A, Ghorai P, Ye QZ, Elz S, Buschauer A, Seifert R (June 2006). "N1-(3-cyclohexylbutanoyl)-N2-[3-(1H-imidazol-4-yl)propylguanidine (UR-AK57), a potent partial agonist for the human histamine H1- and H2-receptors"]. The Journal of Pharmacology and Experimental Therapeutics 317 (3): 1262–8. doi:10.1124/jpet.106.102897. PMID 16554355. http://jpet.aspetjournals.org/cgi/reprint/317/3/1262.pdf.  
  2. ^ Ziemek R, Schneider E, Kraus A, Cabrele C, Beck-Sickinger AG, Bernhardt G, Buschauer A (2007). "Determination of affinity and activity of ligands at the human neuropeptide Y Y4 receptor by flow cytometry and aequorin luminescence". Journal of Receptor and Signal Transduction Research 27 (4): 217–33. doi:10.1080/10799890701505206. PMID 17885919.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message